Stockscreener 앱 받기
3.03
38.36%
0.84
시간 외 거래:
2.98
-0.05
-1.65%
전일 마감가:
$2.19
열려 있는:
$2.2
하루 거래량:
6.13M
Relative Volume:
21.61
시가총액:
$428.47M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+61.17%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$2.10
$3.04
1주일 범위
$1.70
$3.04
52주 변동 폭
$1.70
$26.01
Veraxa Biotech Ag Stock (VRXA) Company Profile
Compare VRXA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRXA
Veraxa Biotech Ag
|
3.03 | 309.68M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veraxa Biotech Ag 주식(VRXA)의 최신 뉴스
VERAXA Biotech (VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - NewMediaWire
Non-controlling/minority interest of Veraxa Biotech AG – BOATS:VRXAW - TradingView
VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - The Globe and Mail
VRXA | Veraxa Biotech AG Ordinary Stock Data, Price & News - Quiver Quantitative
VERAXA Biotech Advances BiTAC Pipeline and Partnering Strategy in First Half of 2026 - citybuzz -
VERAXA Biotech Advances BiTAC Pipeline, Seeks Pharma Partnerships to Fund Cancer Therapies - citybuzz -
VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy - TradingView
The Cancer Therapy Strategy VERAXA Is Betting the Company On - Yahoo Finance
VERAXA Biotech targets 2028 IND filing for lead candidate By Investing.com - Investing.com South Africa
VERAXA Biotech advances cancer therapy pipeline focusing on BiTAC technology and seeks partnerships. - Pluang
VERAXA Biotech AG Provides Pipeline and Partnering Update, Advances BiTAC Development Strategy - Quiver Quantitative
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines - The Manila Times
VERAXA says its BiTAC cancer pipeline is drawing partner interest - Stock Titan
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone - Yahoo Finance
VERAXA Biotech (VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program - NewMediaWire
VERAXA Biotech Begins Cell Line Development for BiTAC Cancer Therapy, Aiming to Improve Tumor Selectivity - citybuzz -
Veraxa Biotech (VRXA) Stock Price, News & Analysis - Stock Titan
Veraxa initiates cell line development for lead cancer therapy By Investing.com - Investing.com Nigeria
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program - The Manila Times
VERAXA advances lead cancer drug toward manufacturing work with ATUM - Stock Titan
Antibody Therapeutics Deals Signal Value Creation for Early-Stage Biotechs Like VERAXA - MEXC
Why VERAXA Biotech (VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals - NewMediaWire
Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sect - Benzinga
Price to earnings forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Enterprise value to EBITDA forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to book forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to sales forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Enterprise value to revenue forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to book forward of Veraxa Biotech AG – NASDAQ:VRXA - TradingView
Price to book forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
VRXA|Veraxa Biotech AG Ord Shs|Price:2.320|Chg%:-0.03 - TradingKey
Price to earnings forward of Veraxa Biotech AG – NASDAQ:VRXA - TradingView
Price to earnings forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Enterprise value to EBIT forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Enterprise value to EBITDA forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Veraxa Biotech AG Ord Shs (VRXA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
VRXA: Veraxa Biotech AGInteractive Chart - Zacks Investment Research
Enterprise value to revenue forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Price to sales forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Price to sales forward of Veraxa Biotech AG – BOATS:VRXA - TradingView
Enterprise value to EBIT forward of Veraxa Biotech AG – BOATS:VRXA - TradingView
Price to earnings forward of Veraxa Biotech AG – BOATS:VRXA - TradingView
Veraxa Biotech Holding AG (FRA:J8L0) Stock PDF (Updated: 2026/06/26) - GuruFocus
Cash per share of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
VERAXA Biotech (VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline - Yahoo Finance
Price to sales forward of Veraxa Biotech AG – BOATS:VRXAW - TradingView
VERAXA Biotech (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline - USA Today
VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Seeks Partnerships at BIO 2026 - MEXC
VERAXA Biotech (VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline - NewMediaWire
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development - Yahoo Finance
Veraxa Biotech expands Heidelberg lab space By Investing.com - Investing.com Australia
Veraxa Biotech Ag (VRXA) 재무 분석
Veraxa Biotech Ag (VRXA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.17%
2.48%
자본화:
|
볼륨(24시간):